The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies

JAMA: The Journal of the American Medical Association

Volumn 274, Issue 8, 1995, Pages 620-625

  Psaty, Bruce M ^a   Koepsell, Thomas D ^a   Siscovick, David S ^b   Heckbert, Susan R ^b   Weiss, Noel S ^b   Lemaitre, Rozenn N ^b   Smith, Nicholas L ^b   Raghunathan, Trivellore E ^b   Rosendaal, Frits R ^c   Wahl, Patricia W ^d   Wagner, Edward H ^e   Furberg, Curt D ^f  

^a Cardiovascular Health Research Unit   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Biostatistics ^*  (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CHOICE; HEART INFARCTION; HYPERTENSION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029161079     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1995.03530080036038     Document Type: Article

References (38)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
2. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330: 1852-1857.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265: 3255-3264.
4. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304: 405-412.
5. Psaty BM, Furberg CD. Treatment trials: morbidity and mortality. In: Izzo JL Jr, Black HR, Taubert KA, eds. Hypertension Primer: The Essentials of High Blood Pressure. Dallas, Tex: American Heart Association; 1993:197-201.
6. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
7. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989-1992: an effect of major clinical trials on clinical practice? JAMA. 1995;273: 1436-1438.
8. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
9. Neaton JD, Grimm RH Jr, Prineas RJ, et al, for the Treatment of Mild Hypertension Research Group. Treatment of Mild Hypertension Study (TOMHS): final results. JAMA. 1993;270:713-724.
10. Beto JA, Bansal VK. Quality of life in the treatment of hypertension: a metaanalysis of clinical trials. Am J Hypertens. 1992;5:192-133.
11. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:1187-1192.
12. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-1297.
13. Furberg CD, Psaty BM, Myers JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. In press.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
15. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992; 327:669-677.
16. Goldbourt R, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E, for the SPRINT Study Group. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med. 1993;153:345-353.
17. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109-1113.
18. Dahlof B, Hansson L, Lindholm LH, et al. STOP-Hypertension 2: a prospective intervention trial of newer versus older treatment alternatives in old patients with hypertension: Swedish Trial in Old Patients With Hypertension. Blood Press. 1993;2:136-141.
19. Amery A, Birkenhager W, Bulpitt CJ, et al. SYSTEUR—a multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging. 1991;3:287-302.
20. The NORDIL Group. The Nordic Diltiazem Study (NORDIL): a prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press. 1993;2:314-321.
21. Davis BR, Cutler JA, Gordon DJ, Furberg CD, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. In press.
22. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023-1038.
23. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154: 1333-1339.
24. Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. β-Blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA. 1989;261:2087-2094.
25. Psaty BM, Koepsell TD, Siscovick D, et al. An approach to several problems in the use of large databases for population-based case-control studies of the therapeutic efficacy and safety of antihypertensive medicines. Stat Med. 1991;10:653-662.
26. Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. The relative risk of myocardial infarction in patients who have high blood pressure and non-cardiac chest pain. J Gen Intern Med. 1987; 2:381-387.
27. Sewester CS, Dombek CE, Olin BR, Kastrup EK, Hebel SK, eds. Drug Facts and Comparisons. St Louis, Mo: Facts and Comparisons; 1994.
28. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. New York, NY: Oxford University Press; 1982.
29. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 1: The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980. IARC Scientific Publications No. 32.
30. Rohlfing JJ, Brunzell JD. The effects of diuretics and adrenergic-blocking agents on plasma lipids. West J Med. 1986;145:210-218.
31. McClellan K. Unexpected results from MIDAS in atherosclerosis [summary of results presented at the 15th Scientific Meeting of the International Society of Hypertension in Melbourne, Australia, March 1994]. Inpharma Wkly. 1994;932:4.
32. Ferguson JJ, Momomura S. Highlights from the 58th annual scientific meeting of the Japanese Circulation Society. Circulation. 1994;90:2194-2196.
33. Furberg CD, Byington RP, Borhani NA, for the MIDAS Research Group. Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): design features. Am J Med. 1989;86(suppl 4A):37-39.
34. Wagenknecht L, Furberg CD, Hammon J, Legault C, Troost T. Surgical bleeding: an unexpected effect of calcium antagonists? BMJ. 1995; 310:776-777.
35. Egstrup K, Andersen PE. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol. 1993;71:177-183.
36. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JM, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:2815-2825.
37. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733-743.
38. Hillegass WB, Ohman EM, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol. 1994;73:835-839.